Table 1 Baseline demographics and clinical characteristics
From: The role of optical coherence tomography guidance in scaffold versus stent optimization
Characteristic | Absorb scaffold (N = 162) | Everolimus-DES (N = 61) | p value |
|---|---|---|---|
No. (%) | No. (%) | ||
Male | 122(75.3%) | 47(77.0%) | 0.787 |
Age/years | 54.36 ± 10.02 | 54.13 ± 10.89 | 0.805 |
Body mass index | 28.93 ± 4.17 | 28.97 ± 5.32 | 0.361 |
Hypertension | 104(64.2%) | 35(57.4%) | 0.349 |
Diabetes mellitus | 93(57.4%) | 41(67.2%) | 0.183 |
 Insulin-treated | 29(17.9%) | 15(24.6%) | 0.263 |
Dyslipidemia | 120(74.1%) | 46(75.4%) | 0.838 |
Current smoker | 57(36.5%) | 23(37.7%) | 0.873 |
Previous myocardial infarction | 25(15.4%) | 10(16.4%) | 0.860 |
Post-CABG | 2(1.2%) | 3(4.9%) | 0.127 |
Clinical presentation: | Â | Â | Â |
 Silent ischemia | 19(11.7%) | 7(11.5%) | 0.958 |
 Stable angina | 50(30.9%) | 21(34.4%) | 0.611 |
 Unstable angina/NSTEMI | 63(38.9%) | 28(45.9%) | 0.928 |
 Primary PCI | 20(12.3%) | 4(6.6%) | 0.214 |
 Late or lysed STEMI | 10(6.2%) | 1(1.6%) | 0.297 |